- Previous Close
139.00 - Open
136.00 - Bid 132.00 x --
- Ask 133.00 x --
- Day's Range
127.00 - 139.00 - 52 Week Range
97.00 - 277.00 - Volume
2,041,000 - Avg. Volume
4,064,520 - Market Cap (intraday)
12.438B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.28 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
www.reprocell.comRecent News: 4978.T
View MorePerformance Overview: 4978.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4978.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4978.T
View MoreValuation Measures
Market Cap
12.44B
Enterprise Value
8.01B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.57
Price/Book (mrq)
1.40
Enterprise Value/Revenue
2.94
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.05%
Return on Assets (ttm)
-1.92%
Return on Equity (ttm)
-1.32%
Revenue (ttm)
2.72B
Net Income Avi to Common (ttm)
-110M
Diluted EPS (ttm)
-1.28
Balance Sheet and Cash Flow
Total Cash (mrq)
4.43B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--